<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Content Us</title>
    <link rel="stylesheet" href="css/style.css">
    <script src="https://cdnjs.cloudflare.com/ajax/libs/html2canvas/1.4.1/html2canvas.min.js"></script>
</head>
<body data-page="zn-content">
    <nav>
        <ul>
            <li><a href="index.html">Home Page</a></li>
            <li><a href="members.html">Members</a></li>
            <li><a href="materials.html">Publication</a></li>
            <li><a href="recent.html">News</a></li>
            <li><a href="about.html">Introduction</a></li>
        </ul>
    </nav>

    <nav class="sub-nav">
        <ul>
            <li><a href="professors.html">Back to the previous page</a></li>
            <li><a href="#" id="take-screenshot">Take a screenshot</a></li>
        </ul>
    </nav>

    <div class="container">
        <div class="new-member-profile professor-detail">
            <div class="special-con">
                <div class="special-con">
                    <img src="images/Professor/CongcongXu.jpg" alt="Congcong Xu">
                    <div class="name-title">Congcong Xu</div>
                    <div class="position-subtitle">
                        <b>Associate Professor</b>
                    </div>
                </div>
            </div>
            <div>
                <h1>Personal Profile</h1>
                <br>
                <h3>Congcong Xu, Ph.D.</h3>
                <ul class="normal">
                    <li>Young Distinguished Professor, International College of Pharmaceutical Innovation, Soochow University</li>
                </ul>
                <h3>Education Background</h3>
                <ul class="normal">
                    <li>Bachelor of Chemistry, Hunan University (2015)</li>
                    <li>Ph.D. in Pharmaceutical Sciences, The Ohio State University College of Pharmacy (2020), supervised by Prof. Peixuan Guo (Member of the National Academy of Inventors, USA)</li>
                </ul>
                <h3>Professional Experience</h3>
                <ul class="normal">
                    <li>2020–2023: Head of mRNA Platform R&D at a leading mRNA biotech company, advancing three mRNA drugs and vaccines to obtain clinical IND approvals, and one mRNA vaccine to receive emergency use authorization.</li>
                </ul>
                <h3>Research Funding</h3>
                <ul class="normal">
                    <li>Principal Investigator of the Shanghai Science and Technology Innovation Action Plan Project</li>
                    <li>Principal Investigator of the High-Level Talent Research Project at Soochow University</li>
                    <li>Participating Researcher in a National Key R&D Program Project</li>
                </ul>
                <h3>Academic Achievements</h3>
                <ul class="normal">
                    <li>First/co-corresponding author of multiple papers in international journals including Nature, Science Advances, Nano Today, and Nano Research.</li>
                    <li>Holder of 5 authorized international patents, with 4 domestic invention patent applications submitted in the field of RNA therapeutics.</li>
                </ul>
            </div>
        </div>

        <div class="new-member-profile honors-list">
           <h1>Personal statement</h1>
        </div>

        <div class="new-member-profile honors-list">
            <ul class="normal-pl">
                <li>I, Congcong Xu, graduated from Hunan University (Changsha, China) with Bachelor degree in science majoring in Chemistry under the supervision of Prof. Weihong Tan. The undergraduate research project involving nucleic acid 
                    nanotechnology took me to the field of non-viral drug delivery, especially nucleic acid-based nanocarriers. Then I joined Prof. Peixuan Guo’s laboratory at The Ohio State University to pursue my PhD degree in Pharmaceutical 
                    Sciences (Columbus, USA). My PhD research was mainly focusing on developing novel RNA nanoparticle-based delivery systems for controlled drug release and in vivo cancer targeting. By rationally designing RNA sequences, 
                    multiple RNA molecules could self-assemble into a uniform nanostructure with well-defined size and architecture. By conjugating therapeutic drugs or RNA such as siRNA or anti-miRNA, the RNA nanoparticles could be engineered 
                    for versatile applications. During the PhD training, I obtained in-depth understanding of RNA molecule in terms of structure and chemical properties, as well as non-viral nanodelivery systems.</li>
 
                <li>At the time of PhD graduation (2020/05), the COVID-19 pandemic was causing a public health crisis globally.  I recognized the promises of mRNA technology in developing efficacious vaccines against SARS-Cov-2 and I joined a 
                    biotech company StemiRNA Therapeutics as senior scientist, mainly working on exploring novel mRNA platforms for vaccine and therapeutic development. The burgeoning field of mRNA vaccine in industry attracted unprecedented 
                    investment and attraction. I was in charge of mRNA platform research and development department and led a team with 10 scientists. By collaboration with Baidu Research Institute on artificial intelligence algorithm, we aimed 
                    to use AI technology for rapid design of mRNA sequences with high stability and translation efficiency. It took us more than two years to adjust the algorithm for rational mRNA sequence readout as the in vivo performance of 
                    mRNA molecules are actually impacted by many factors; and we successfully found the “sweet spot” for mRNA sequence when balancing its stability with translation efficiency. This work was finally accepted by Nature and published 
                    as accelerated article preview. </li>
                     
                <li>Then I further extended the algorithm to circular RNA by inventing circDesign in collaboration with researcher from China Pharmaceutical University. The circular RNA has a different structure and translation mechanism. This 
                    was benefited from my PhD training in understanding the structure of RNA structures. Recently, I relocated to Soochow University as an Associate Professor at the International College of Pharmaceutical Innovation. My current 
                    research focus is on the AI-based design of mRNA therapeutics for tailored in vivo performance. The mRNA technology made itself as a platform for vaccine or therapeutic purpose; I believe the mRNA molecules, as the key drug 
                    substance, would need to be rationally designed for versatile applications.</li>
                    
                <li>Therefore, I have accumulated about 10 years of research experience in the field of nucleic acid, drug delivery and RNA therapeutics. With three years of industry experience, I formed a different viewpoint when conducting 
                    research activity as I always think about the significance in terms of pharmaceutical development.</li>
            </ul>
        </div>

        <div class="new-member-profile honors-list">
            <h1>Education</h1>
        </div>

        <div class="new-member-profile honors-list">
            <table>
                <thead>
                    <tr>
                        <th>Time</th>
                        <th>Degree</th>
                        <th>Colleges</th>
                        <th>Mentor</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>01/2016 - 2020/07</td>
                        <td>Ph.D. in Pharmaceutical Sciences</td>
                        <td>Department of Pharmaceutical Science, College of Pharmacy, The Ohio State University</td>
                        <td>Dr. Peixuan Guo</td>
                    </tr>
                    <tr>
                        <td>08/2015 - 12/2015</td>
                        <td>Ph.D. in Pharmaceutical Sciences</td>
                        <td>Department of Pharmaceutical Science, College of Pharmacy, University of Kentucky</td>
                        <td>Dr. Peixuan Guo</td>
                    </tr>
                    <tr>
                        <td>09/2011 - 06/2015</td>
                        <td>B.S. in Chemistry</td>
                        <td>School of Chemistry and Chemical Engineering, Hunan University</td>
                        <td>Dr. Weihong Tan & Dr. Xiaohai Yang</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="new-member-profile honors-list">
            <h1>Employment and Affiliations</h1>
        </div>

        <div class="new-member-profile honors-list">
            <table>
                <thead>
                    <tr>
                        <th>Time</th>
                        <th>Position</th>
                        <th>Institution</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>11/2023 - present</td>
                        <td>Assoc. Prof.</td>
                        <td>International College of Pharmaceutical Innovation, Soochow Univ.</td>
                    </tr>
                    <tr>
                        <td>11/2023 - present</td>
                        <td>Member</td>
                        <td>Soochow University Biomedical Polymers Laboratory</td>
                    </tr>
                    <tr>
                        <td>01/2022 - present</td>
                        <td>Member</td>
                        <td>Center for Shanghai International mRNA Innovation, Shanghai</td>
                    </tr>
                    <tr>
                        <td>12/2020 - 10/2023</td>
                        <td>Member</td>
                        <td>Center for mRNA Emergency Vaccine Innovation Technology, Shanghai</td>
                    </tr>
                    <tr>
                        <td>04/2021 - 10/2023</td>
                        <td>Principle Investigator, Head of mRNA Platform</td>
                        <td>StemiRNA Therapeutics, Shanghai</td>
                    </tr>
                    <tr>
                        <td>08/2020 - 03/2021</td>
                        <td>Principle Scientist</td>
                        <td>StemiRNA Therapeutics, Shanghai</td>
                    </tr>
                    <tr>
                        <td>10/2017 - 07/2020</td>
                        <td>Member</td>
                        <td>International Society of RNA Nanotechnology and Nanomedicine</td>
                    </tr>
                    <tr>
                        <td>01/2016 - 07/2020</td>
                        <td>Research Assistant</td>
                        <td>College of Pharmacy, The Ohio State University</td>
                    </tr>
                    <tr>
                        <td>01/2016 - 07/2020</td>
                        <td>Member</td>
                        <td>Center for RNA Nanobiotech. & Nanomed., The Ohio State University</td>
                    </tr>
                    <tr>
                        <td>08/2015 - 12/2015</td>
                        <td>Research Assistant</td>
                        <td>College of Pharmacy, University of Kentucky</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="new-member-profile honors-list">
            <h1>Awards</h1>
        </div>

        <div class="new-member-profile honors-list">
            <table>
                <thead>
                    <tr>
                        <th>Time</th>
                        <th>Hornor</th>
                        <th>Company</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>02/2023</td>
                        <td>Star of R & D; Great Team Leader</td>
                        <td>StemiRNA Therapeutics</td>
                    </tr>
                    <tr>
                        <td>10/2022</td>
                        <td>Shanghai Pujiang Talent</td>
                        <td>Commission of Science & Technology of Shanghai</td>
                    </tr>
                    <tr>
                        <td>02/2022</td>
                        <td>Outstanding Middle-class Management Award</td>
                        <td>StemiRNA Therapeutics</td>
                    </tr>
                    <tr>
                        <td>01/2021</td>
                        <td>Outstanding New Recruits Award</td>
                        <td>StemiRNA Therapeutics</td>
                    </tr>
                    <tr>
                        <td>10/2019</td>
                        <td>2nd Place Pre-Doctoral Graduate Student Poster Award</td>
                        <td>The Ohio State Univ.</td>
                    </tr>
                    <tr>
                        <td>11/2018</td>
                        <td>Betty - ann Hoener Award</td>
                        <td>The Ohio State University</td>
                    </tr>
                    <tr>
                        <td>09/2016</td>
                        <td>Chang Ahn Foundation Travel Award</td>
                        <td>The Ohio State University</td>
                    </tr>
                    <tr>
                        <td>06/2015</td>
                        <td>Excellent Undergraduate</td>
                        <td>Hunan University</td>
                    </tr>
                    <tr>
                        <td>10/2014</td>
                        <td>Sun Hung Kai Properties Scholarship</td>
                        <td>Hunan University</td>
                    </tr>
                    <tr>
                        <td>09/2014</td>
                        <td>Haozhi Scholarship</td>
                        <td>Hunan University</td>
                    </tr>
                    <tr>
                        <td>07/2014</td>
                        <td>The First Prize of “SIT” program</td>
                        <td>Hunan University</td>
                    </tr>
                    <tr>
                        <td>09/2013</td>
                        <td>Hongyuyan Scholarship</td>
                        <td>Hunan University</td>
                    </tr>
                    <tr>
                        <td>10/2013</td>
                        <td>Sun Hung Kai Properties Scholarship</td>
                        <td>Hunan University</td>
                    </tr>
                    <tr>
                        <td>10/2012</td>
                        <td>National Encouragement Scholarship</td>
                        <td>Hunan University</td>
                    </tr>
                    <tr>
                        <td>10/2012</td>
                        <td>Excellent Student Cadre</td>
                        <td>Hunan University</td>
                    </tr>
                    <tr>
                        <td>10/2012</td>
                        <td>Sun Hung Kai Properties Scholarship</td>
                        <td>Hunan University</td>
                    </tr>
                    <tr>
                        <td>12/2011</td>
                        <td>Tianjian Scholarship</td>
                        <td>Hunan University</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="new-member-profile honors-list">
            <h1>Representative Papers</h1>
        </div>

        <div class="new-member-profile honors-list">
            <table>
                <thead>
                    <tr>
                        <th>Serial Number</th>
                        <th>Author</th>
                        <th>Title of the Paper</th>
                        <th>Periodical</th>
                        <th>Publication Time</th>
                        <th>DOI</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>1</td>
                        <td>Ye, R., Ren, Q., Chang, L., Zhang, S., Deng, C., Cao, L., Shi, M., Lou, B., Meng, F., Du, S., Ren, K., Piao, X., Xu, C.*, Zhong, Z.*</td>
                        <td>Administration route-commended concise organ-selective mRNA transfection (ACCOST) by cyclic disulfide-primed short polyethylenimine.</td>
                        <td>Nano Today</td>
                        <td>2025 Aug</td>
                        <td>10.1016/j.nantod.2025.102741</td>
                    </tr>
                    <tr>
                        <td>2</td>
                        <td>Xu, C., Pu, C., Chen, R., Wang, W., Jiang, F., Deng, C., ... & Zhang, L.</td>
                        <td>circDesign Algorithm for Designing Synthetic Circular RNA.</td>
                        <td>bioRxiv</td>
                        <td>2023</td>
                        <td>10.1101/2023.07.09.548293v3</td>
                    </tr>
                    <tr>
                        <td>3</td>
                        <td>Fan T#, Xu C# (co-first author), Wu J#, Cai Y, Cao W, Shen H, Zhang M, Zhu H, Yang J, Zhu Z, Ma X, Ren J, Huang L, Li Q, Tang Y, Yu B, Chen C, Xu M, Wang Q, Xu Z, Chen F, Liang S, Zhong Z, Jamroze A, Tang DG, Li H, Dong C.</td>
                        <td>Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity.</td>
                        <td>Sci Adv.</td>
                        <td>2024 Oct 11</td>
                        <td>10.1126/sciadv.adn9961</td>
                    </tr>
                    <tr>
                        <td>4</td>
                        <td>Cui G, Shao Y, Wang J, Xu C*, Jinping Zhang*, Zhiyuan Zhong*</td>
                        <td>Polymersome-mediated Cbl-b silencing activates T cells against solid tumors.</td>
                        <td>Biomater. Sci.</td>
                        <td>2025</td>
                        <td>10.1039/D5BM00001G</td>
                    </tr>
                    <tr>
                        <td>5</td>
                        <td>Xu C, Yin H, Yudhistira T, Li Z, Binzel D,*Guo P*</td>
                        <td>Conversion of Chemical Drugs into Targeting Ligands on RNA Nanoparticles and Assessing Payload Stoichiometry for Optimal Biodistribution in Cancer Treatment.</td>
                        <td>RNA NanoMed</td>
                        <td>2024</td>
                        <td>10.59566/ISRNN.2024.0101109</td>
                    </tr>
                    <tr>
                        <td>6</td>
                        <td>Zhang, H.#, Zhang, L.#, Lin, A. #, Xu, C. # (co-first author), Li, Z., Liu, K., ... & Huang, L.</td>
                        <td>Algorithm for optimized mRNA design improves stability and immunogenicity.</td>
                        <td>Nature</td>
                        <td>2023</td>
                        <td>10.1038/s41586-023-06127-z</td>
                    </tr>
                    <tr>
                        <td>7</td>
                        <td>Yi Fang, Jing-Xin Li, Davone Duangdany, Yang Li, Xi-Lin Guo, Chanthala Phamisith, Ming-Yun Shen, Bo Yu, Bin Luo, Yu-Zhu Wang, Si-Jun Liu, Fan-Fan Zhao, Cong-Cong Xu, Xu-Hui Qiu, Rong-Juan Pei, Jie Wang, Haifa Shen, Wu-Xiang Guan, Hang-Wen Li, Mayfong Mayxay</td>
                        <td>Safety, immunogenicity and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: interim report of a Phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos).</td>
                        <td>EClinicalMedicine</td>
                        <td>2023 Dec 13</td>
                        <td>10.1016/j.eclinm.2023.102372</td>
                    </tr>
                    <tr>
                        <td>8</td>
                        <td>Carcache PJ, Guo S, Li H, Zhang K, Xu C, Chiu W, Guo P.</td>
                        <td>Regulation of reversible conformational change, size switching, and immunomodulation of RNA nanocubes.</td>
                        <td>RNA</td>
                        <td>2021 Sep 1</td>
                        <td>10.1261/rna.078718.121.</td>
                    </tr>
                    <tr>
                        <td>9</td>
                        <td>Guo S., Xu C., Yin H., Hill J., Pi F., Guo P.</td>
                        <td>Tuning the size, shape and structure of RNA nanoparticles for favorable cancer targeting and immunostimulation.</td>
                        <td>WIREs Nanomedicine and Nanobiotechnology</td>
                        <td>2019 Aug 27</td>
                        <td>10.1002/wnan.1582</td>
                    </tr>
                    <tr>
                        <td>10</td>
                        <td>Xu, C., Zhang, K., Yin, H., Li, Z., Krasnoslobodtsev, A., Zheng, Z., Ji, Z., Guo, S., Li, S., Chiu, W. and Guo, P.</td>
                        <td>3D RNA nanocage for encapsulation and shielding of hydrophobic biomolecules to improve the in vivo biodistribution.</td>
                        <td>Nano Research</td>
                        <td>2020</td>
                        <td>10.1007/s12274-020-2996-1</td>
                    </tr>
                    <tr>
                        <td>11</td>
                        <td>Chen, Y., Li, J., Duangdany, D., Phamisith, C., Yu, B., Lan, S., Jin, L., Lv, D., Li, Y., Luo, B., Han, P., Wu, J., Wang, Y., Xu, C., Shen, M., Zhao, F., Liu, P., Pei, R., Shen, H., Guan, W., Li, H., Mayxay, M.</td>
                        <td>Safety and Immunogenicity of SW-BIC-213, a Modified COVID-19 Lipo-Polyplex Mrna Vaccine, in Laotian Healthy Adults Aged 18 Years and Above: a Phase 1/2 Trial</td>
                        <td>Openalex</td>
                        <td>2023</td>
                        <td>10.1101/2023.09.11.23295344</td>
                    </tr>
                    <tr>
                        <td>12</td>
                        <td>Ghimire C, Wang H, Li H, Vieweger M, Xu C, Guo P.</td>
                        <td>RNA nanoparticles as rubber for compelling vessel extravasation to enhance tumor targeting and for fast renal excretion to reduce toxicity.</td>
                        <td>ACS Nano</td>
                        <td>2020 Sep 9</td>
                        <td>10.1021/acsnano.0c04863</td>
                    </tr>
                    <tr>
                        <td>13</td>
                        <td>Li H., Wang S., Ji Z., Xu C., Shlyakhtenko L.S. and Guo P.</td>
                        <td>Construction of RNA nanotubes.</td>
                        <td>Nano Research</td>
                        <td>2019</td>
                        <td>10.1007/s12274-019-2463-z</td>
                    </tr>
                    <tr>
                        <td>14</td>
                        <td>Zheng Z, Li Z, Xu C, Guo B, Guo P.</td>
                        <td>Folate-displaying exosome mediated cytosolic delivery of siRNA avoiding endosome trapping.</td>
                        <td>J Control Release</td>
                        <td>2019 Aug 22</td>
                        <td>10.1016/j.jconrel.2019.08.021</td>
                    </tr>
                    <tr>
                        <td>15</td>
                        <td>Yin H, Xiong G, Guo S, Xu C, Xu R, Guo P, Shu D.</td>
                        <td>Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133.</td>
                        <td>Mol Ther.</td>
                        <td>2019 Jul 3</td>
                        <td>10.1016/j.ymthe.2019.04.018</td>
                    </tr>
                    <tr>
                        <td>16</td>
                        <td>Xu Y, Pang L, Wang H, Xu C, Shah H, Guo P, Shu D, Qian SY.</td>
                        <td>Specific delivery of delta-5-desaturase siRNA via RNA nanoparticles supplemented with dihomo-γ-linolenic acid for colon cancer suppression.</td>
                        <td>Redox Biol.</td>
                        <td>2019 Feb</td>
                        <td>10.1016/j.redox.2018.101085</td>
                    </tr>
                    <tr>
                        <td>17</td>
                        <td>Xu C, Li H, Zhang K, Binzel DW, Yin H, Chiu W, Guo P.</td>
                        <td>Photo-controlled release of paclitaxel and model drugs from RNA pyramids.</td>
                        <td>Nano Res.</td>
                        <td>2019 Jan</td>
                        <td>10.1007/s12274-018-2174-x</td>
                    </tr>
                    <tr>
                        <td>18</td>
                        <td>Xu C, Haque F, Jasinski DL, Binzel DW, Shu D, Guo P.</td>
                        <td>Favorable biodistribution, specific targeting and conditional endosomal escape of RNA nanoparticles in cancer therapy.</td>
                        <td>Cancer Lett.</td>
                        <td>2018 Feb 1</td>
                        <td>10.1016/j.canlet.2017.09.043</td>
                    </tr>
                    <tr>
                        <td>19</td>
                        <td>Li W, Yang X, He L, Wang K, Wang Q, Huang J, Liu J, Wu B, Xu C.</td>
                        <td>Self-Assembled DNA Nanocentipede as Multivalent Drug Carrier for Targeted Delivery.</td>
                        <td>ACS Appl Mater Interfaces</td>
                        <td>2016 Oct 5</td>
                        <td>10.1021/acsami.6b08210</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="new-container">
            <div class="member-profile">
                <div class="content-card text-animate">
                    <h2>Contect us
                    </h2>
                    <ul class="honors-list">
                        <li>Talk to us face to face:</li>
                    </ul>
                    <ul class="big">
                        <li>We look forward to your help and advice, if you would like to join us or learn more, please contact us</li>
                    </ul>
                    <a href="zn-content.html">
                        <p>Click here for contact details</p>
                    </a>
                </div>
            </div>

        </div>
    </div>
    <footer>
        <p>© 2025 xRNA-Lab All rights reserved</p>
    </footer>

    <script src="js/script.js"></script>
</body>
</html>

